Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Immunomedics
Immunomedics
Biotech Buzz: ASCO Winners and Losers and Biogen's Discouraging Failure
Motley Fool
Fri, 06/10/16 - 04:16 pm
biotech
ASCO 2016
Biogen
Immunomedics
AbbVie
Juno Therapeutics
Kite Pharma
Immunomedics Kicked Out of Prestigious ASCO Cancer Conference
TheStreet.com
Fri, 06/3/16 - 09:49 am
Immunomedics
triple negative breast cancer
ASCO 2016
IMMU-132
10 Worst NASDAQ Biotech Stocks in the Third Quarter
TheStreet.com
Wed, 09/30/15 - 07:51 pm
Orexigen
Immunomedics
Celldex Therapeutics
Arena Pharmaceuticals
Theravance
Karyopharm
Raptor Pharmaceutical
Verastem
Tetraphase
Xoma
How 6 ASCO Biotech Winners Are Focusing on the Future of Cancer
24/7 Wall St
Sun, 06/7/15 - 10:07 am
biotech
ASCO
Immunogen
Exelixis
Oncothyreon
CTI BioPharma
Immunomedics
Vascular Biogenics
16 Biotech Stocks Moving Off The ASCO Conference
Yahoo/Benzinga
Tue, 06/2/15 - 10:06 am
biotech
ASCO
Bristol-Myers Squibb
Immunogen
Oncothyreon
Clovis Oncology
CTI BioPharma
Exelixis
Roche
Amgen
AstraZeneca
Puma Biotechnology
Vascular Biogenics
Immunomedics
Momenta
Eli Lilly
Juno Therapeutics
Express Scripts
6 Key Cancer Winners From ASCO Presentations
24/7 Wall St
Mon, 06/1/15 - 10:06 am
ASCO
Immunogen
mirevtuximab soravtansine
ONT-380
Oncothyreon
cabozantinib
Exelixis
VB-111
Vascular Biogenics
Immunomedics
sacituzumab govitecan
pacritinib
CTI BioPharma
Patients With Advanced Breast, Lung, Esophageal, and Colorectal Cancers Respond to Immunomedics' Novel Antibody-Directed Chemotherapy After Failing Multiple Prior Standard Treatments
Yahoo
Mon, 04/20/15 - 05:15 pm
Immunomedics
chemotherapy
breast cancer
lung cancer
esophageal cancer
colorectal cancer
sacituzumab govitecan
Immunomedics Inc announces orphan drug designation for IMMU-132 for Pancreatic Cancer Therapy
Reuters
Mon, 06/9/14 - 09:21 am
IMMU-132
orphan drugs
Immunomedics
pancreatic cancer
Immunomedics Reports Final Efficacy Results of Phase Ib Trial With Yttrium-90-Labeled Clivatuzumab Tetraxetan in Patients With Metastatic Pancreatic Cancer
Yahoo/Globe Newswire
Sun, 06/1/14 - 11:31 am
Immunomedics
pancreatic cancer
clivatuzumab tetraxetan
gemcitabine
Immunomedics' (IMMU) CEO Cynthia Sullivan on F3Q 2014 Results - Earnings Call Transcript
Seeking Alpha
Sun, 05/11/14 - 10:48 am
Immunomedics
earnings
Immunomedics reports results from three IMMU-130 phase I trials
Yahoo/Fly on the Wall
Mon, 04/7/14 - 12:59 pm
Immunomedics
IMMU-130
colorectal cancer
Oppenheimer Sees Five Biotech Stocks to Buy With Potential 50% Upside, or More
24/7 Wall St
Tue, 01/7/14 - 11:47 am
Celldex Therapeutics
Immunomedics
Keryx
Merrimack Pharmaceuticals
Protalix BioTherapeutics
A Look Back at Immunomedics' Volatile but Rewarding 2013
Motley Fool
Wed, 12/11/13 - 09:32 am
Immunomedics
Immunomedics says lung cancer drug IMMU-132 gets orphan drug incentives from FDA
Yahoo/AP
Wed, 12/4/13 - 03:43 pm
Immunomedics
IMMU-132
orphan drugs
small cell lung cancer
3 Biotechs on the Move This Week
Motley Fool
Fri, 11/8/13 - 11:55 am
Immunogen
IMGN901
Immunomedics
Takeda
imetelstat
Geron
Immunomedics announces IMMU-132 is active in patients refractory to Irinotecan
Yahoo/
Fri, 11/8/13 - 09:13 am
IMMU-132
Immunomedics
solid tumors
3 Biotechs Falling Like a Knife
Motley Fool
Wed, 11/6/13 - 08:26 am
Immunomedics
Inovio
Ariad Pharmaceuticals
This Week in Biotech
Motley Fool
Sun, 10/27/13 - 12:48 pm
Immunomedics
Zogenix
Gilead Sciences
Osiris Therapeutics
Repros Therapeutics
Biotech Stock Bubble Debate in 14 Charts
TheStreet.com
Wed, 10/23/13 - 08:32 am
biotech
Bluebird Bio
Celgene
Celldex
Onconova
Aegerion
Receptos
Immunomedics
Alcobra
Gilead
Biogen Idec
Ambit Biosciences
Which Of These Smaller Companies Could Roche Buy?
Motley Fool
Sat, 08/17/13 - 10:50 am
Roche
M&A
Celldex
ImmunoCellular Therapeutics
Immunomedics
Alexion
Pages
« first
‹ previous
1
2
3
4
next ›
last »